NCT06790056Completed
Efficacy of Endoscopic Band Ligation (DEBL) for Duodenal Neuroendocrine Neoplasms(dNENs)
Efficacy of Endoscopic Band Ligation (DEBL) for Duodenal Neuroendocrine Neoplasms(dNENs) : A Prospective Study
Source: ClinicalTrials.gov · Last updated 23 Jan 2025
Brief summary (registry, in English)
Primary objective To evaluate the therapeutic efficacy (clinical success) of dEBL at 3 months 2b. Secondary objective To evaluate adverse events, technical success and recurrence on follow-up 50 patients over 1-year duration based on our previous study of Prospective data (2023-2024)
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 50 (actual)
- First submitted
- 11 Jan 2024
- Start date
- 29 Feb 2024
- Primary completion date
- 10 Nov 2024
- Lead sponsor
- Asian Institute of Gastroenterology, India
- Diseases
- Neuroendocrine tumours
- NCT number
- NCT06790056
What you commit to
- Study type: Observational
- Participants enrolled: 50
- From 29 Feb 2024 to the primary completion date, 10 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Age less than 18 years
Other
- Non-duodenal lesion
- Local or distant metastasis
- Lumen occluding lesions
- Uncorrectable coagulopathy
- Not willing for consent
Who the study is looking for
- Patients age \>18 years
- Size of lesion less than 15mm
- Site of lesion- duodenum (d1-d4)
- No of lesions- ≤6
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hardik Rughwani Coordinator of this site? Confirm its status | Hyderabad | India | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.